[go: up one dir, main page]

WO1994021303B1 - Compositions de fluorocarbones comportant un etiquetage visible ou fluorescent - Google Patents

Compositions de fluorocarbones comportant un etiquetage visible ou fluorescent

Info

Publication number
WO1994021303B1
WO1994021303B1 PCT/US1994/002789 US9402789W WO9421303B1 WO 1994021303 B1 WO1994021303 B1 WO 1994021303B1 US 9402789 W US9402789 W US 9402789W WO 9421303 B1 WO9421303 B1 WO 9421303B1
Authority
WO
WIPO (PCT)
Prior art keywords
fluorocarbon
cells
dye
tissues
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/002789
Other languages
English (en)
Other versions
WO1994021303A1 (fr
Filing date
Publication date
Application filed filed Critical
Priority to AU63658/94A priority Critical patent/AU6365894A/en
Publication of WO1994021303A1 publication Critical patent/WO1994021303A1/fr
Publication of WO1994021303B1 publication Critical patent/WO1994021303B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

Composition destinée à la visualisation de tissus et renfermant un fluorocarbone liquide toléré par l'organisme et un étiquetage visualisable tel qu'un chromophore ou une teinture visible ou fluorescente associés à celui-ci; de préférence, ce fluorocarbone est sous forme d'émulsion et l'étiquetage comporte une fraction lipophile. L'invention porte également sur des méthodes d'étiquetage et de visualisation de cellules et de tissus, tels que ceux du système réticulo-endothélial.
PCT/US1994/002789 1993-03-16 1994-03-15 Compositions de fluorocarbones comportant un etiquetage visible ou fluorescent Ceased WO1994021303A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63658/94A AU6365894A (en) 1993-03-16 1994-03-15 Fluorocarbon compositions containing a visible or fluorescent label

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3196093A 1993-03-16 1993-03-16
US08/031,960 1993-03-16

Publications (2)

Publication Number Publication Date
WO1994021303A1 WO1994021303A1 (fr) 1994-09-29
WO1994021303B1 true WO1994021303B1 (fr) 1994-11-10

Family

ID=21862331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002789 Ceased WO1994021303A1 (fr) 1993-03-16 1994-03-15 Compositions de fluorocarbones comportant un etiquetage visible ou fluorescent

Country Status (3)

Country Link
US (1) US5460800A (fr)
AU (1) AU6365894A (fr)
WO (1) WO1994021303A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
IL108416A (en) * 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
CA2252617A1 (fr) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Procedes d'apport de composes dans une cellule
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US5951965A (en) * 1998-08-28 1999-09-14 Colgate Palmolive Company Method for visually demonstrating the effectiveness of an anti-bacteria attachment composition
SE9804328D0 (sv) * 1998-12-15 1998-12-15 Christer Busch Contrast agent for facilitating ocular identification and inspection of lymph nodes
EP1088559A3 (fr) * 1999-09-29 2002-10-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Formulations galéniques
EP1419787A1 (fr) * 2002-11-18 2004-05-19 Uwe Prof. Dr. Till Composé destiné à l'identification du ganglion lymphatique
CA2560544C (fr) * 2004-01-16 2015-05-19 Carnegie Mellon University Marquage cellulaire pour des techniques de resonance magnetiques nucleaires
AU2007238586B2 (en) 2006-04-14 2014-03-20 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
EP2012832A2 (fr) * 2006-04-14 2009-01-14 Celsense, Inc. Procédés de détermination du marquage de cellules
JP5645658B2 (ja) 2007-07-10 2014-12-24 カーネギー メロン ユニバーシティー 核磁気共鳴技術のための細胞標識を製造するための組成物及び方法
ES2611103T3 (es) * 2008-05-02 2017-05-04 Celsense Inc. Composiciones y métodos para producir emulsiones para técnicas de resonancia magnética nuclear y otras aplicaciones
US20160296642A1 (en) * 2013-12-06 2016-10-13 Celsense, Inc. Compositions and Methods to Image and Quantify Inflammation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4891208A (en) * 1985-04-10 1990-01-02 The Liposome Company, Inc. Steroidal liposomes
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4783401A (en) * 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
US4762701A (en) * 1986-10-31 1988-08-09 Smithkline Beckman Corporation In vivo cellular tracking
US4832992A (en) * 1986-12-23 1989-05-23 Fuji Photo Film Co., Ltd. Process for the preparation of information recording medium
JPS63191687A (ja) * 1987-02-04 1988-08-09 Fuji Photo Film Co Ltd 情報記録媒体の製造法
US4951673A (en) * 1988-08-19 1990-08-28 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions

Similar Documents

Publication Publication Date Title
WO1994021303B1 (fr) Compositions de fluorocarbones comportant un etiquetage visible ou fluorescent
Fowler et al. Application of Nile red, a fluorescent hydrophobic probe, for the detection of neutral lipid deposits in tissue sections: comparison with oil red O.
Desmettre et al. Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography
Skalak et al. New morphological evidence for a mechanism of lymph formation in skeletal muscle
Leo et al. Hepatic fibrosis after long‐term administration of ethanol and moderate vitamin A supplementation in the rat
Bull et al. Neuropeptides induce release of nitric oxide from human dermal microvascular endothelial cells
Förstermann et al. Species-dependent differences in the nature of endothelium-derived vascular relaxing factor
Yuan et al. Flow modulates coronary venular permeability by a nitric oxide-related mechanism
Lutty The acute intravenous toxicity of biological stains, dyes, and other fluorescent substances
Dormandy et al. The experimental and clinical pathology of diene conjugation
Bentzel et al. Osmotic flow across proximal tubule of Necturus: correlation of physiologic and anatomic studies
Zamlauskitucker et al. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney
US20080154102A1 (en) Intraoperative imaging methods
US20020182112A1 (en) In vivo method for measuring binding of chemical actives to skin or specific constituents of skin
Kök et al. Sudden death due to ruptured hydatid cyst of the liver
Kon et al. A regulatory role for large vessels in organ circulation. Endothelial cells of the main renal artery modulate intrarenal hemodynamics in the rat.
US20030096334A1 (en) Use of injectable dyes for staining an anterior lens capsule and vitreo-retinal interface
Rutledge Temperature and hydrostatic pressure-dependent pathways of low-density lipoprotein transport across microvascular barrier
Guss et al. Rhodamine B as a test molecule in intraocular dynamics.
Kyousola et al. Adrenergic innervation of the human liver
Aziz et al. Oxidative stress mediates monocrotaline-induced alterations in tenascin expression in pulmonary artery endothelial cells
Bret et al. Intrahepatic bile duct and portal vein anatomy revisited.
Goldin et al. Hepatotoxicity of ethanol in mice
US5880123A (en) Hemolysis prevention by non-ionic surfactants
Bank et al. Proximal bicarbonate absorption independent of Na+-H+ exchange: effect of bicarbonate load